Parnax Lab Ltd
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]
- Market Cap ₹ 187 Cr.
- Current Price ₹ 162
- High / Low ₹ 194 / 80.0
- Stock P/E 15.8
- Book Value ₹ 68.8
- Dividend Yield 0.00 %
- ROCE 12.9 %
- ROE 14.3 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 23.8% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
58 | 70 | 103 | 71 | 95 | 106 | 109 | 95 | 90 | 163 | 168 | 189 | 196 | |
50 | 62 | 91 | 61 | 82 | 95 | 99 | 89 | 80 | 140 | 145 | 165 | 168 | |
Operating Profit | 7 | 8 | 12 | 10 | 13 | 10 | 10 | 6 | 10 | 23 | 23 | 24 | 28 |
OPM % | 13% | 12% | 12% | 14% | 14% | 10% | 9% | 7% | 11% | 14% | 14% | 12% | 14% |
1 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | |
Interest | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 |
Depreciation | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 7 | 7 | 7 |
Profit before tax | 3 | 3 | 5 | 3 | 5 | 3 | 5 | -2 | -0 | 12 | 12 | 12 | 16 |
Tax % | 35% | 27% | 22% | 28% | 22% | 65% | 28% | 48% | 350% | 33% | 30% | 20% | |
2 | 2 | 4 | 3 | 4 | 1 | 3 | -3 | -0 | 8 | 9 | 10 | 12 | |
EPS in Rs | 2.01 | 2.93 | 5.01 | 2.95 | 4.33 | 1.23 | 3.88 | -3.42 | -0.42 | 8.40 | 7.51 | 8.37 | 10.29 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 12% |
3 Years: | 28% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 24% |
3 Years: | 203% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 55% |
3 Years: | 64% |
1 Year: | 92% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 10% |
3 Years: | 16% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 11 | 11 | 11 |
Reserves | 10 | 12 | 17 | 19 | 23 | 24 | 27 | 24 | 24 | 37 | 51 | 60 | 67 |
27 | 33 | 41 | 42 | 39 | 37 | 42 | 51 | 59 | 69 | 55 | 81 | 75 | |
15 | 29 | 17 | 10 | 15 | 18 | 17 | 23 | 15 | 38 | 28 | 37 | 26 | |
Total Liabilities | 60 | 83 | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 189 | 180 |
33 | 36 | 36 | 38 | 47 | 44 | 51 | 58 | 60 | 72 | 77 | 89 | 114 | |
CWIP | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 3 | 5 | 3 | 2 | 21 | 1 |
Investments | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
27 | 46 | 45 | 38 | 38 | 43 | 43 | 46 | 41 | 78 | 66 | 79 | 66 | |
Total Assets | 60 | 83 | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 189 | 180 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | -0 | -0 | 3 | 16 | 13 | 9 | 9 | 6 | 9 | 21 | 16 | |
-1 | -6 | -4 | -6 | -10 | -5 | -11 | -13 | -7 | -16 | -10 | -32 | |
-3 | 6 | 6 | 1 | -5 | -7 | 1 | 5 | 0 | 12 | -14 | 15 | |
Net Cash Flow | 1 | 0 | 1 | -2 | 0 | 1 | -1 | 0 | -0 | 4 | -3 | -1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 130 | 84 | 100 | 72 | 65 | 64 | 88 | 68 | 85 | 61 | 63 |
Inventory Days | 72 | 143 | 38 | 64 | 50 | 45 | 52 | 76 | 80 | 73 | 79 | 94 |
Days Payable | 104 | 203 | 51 | 30 | 48 | 45 | 44 | 74 | 46 | 81 | 53 | 70 |
Cash Conversion Cycle | 55 | 71 | 71 | 134 | 74 | 64 | 72 | 90 | 102 | 77 | 86 | 87 |
Working Capital Days | 43 | 75 | 59 | 74 | 34 | 44 | 53 | 77 | 103 | 73 | 67 | 75 |
ROCE % | 14% | 15% | 16% | 11% | 14% | 11% | 12% | 3% | 6% | 17% | 15% | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Nov - Outcome of board meeting and director designation changes.
- Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024 14 Nov
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024
14 Nov - Change of designation for two directors.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Along With Limited Review Report For The Quarter (Q2) And Half Year Ended 30Th September, 2024.
6 Nov - Notice of Board Meeting for financial results approval.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Oct - Confirmation of securities dematerialisation for Q3 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
PLL is a part Naxpar Group and is a WHO-approved and EHS-compliant Company. It is into contract manufacturing of Liquid Orals, Capsules, Ointments, External Powders & Tablets with its manufacturing facility located
at Silvassa.